# Hengrui pharmaceutical newly appoints two R & D executives By [Debra](https://paragraph.com/@debra) · 2022-04-28 --- Our reporter Yan Guowen and Cao Xueping reported from Beijing Zou Jianrui, deputy general manager of the company, announced his resignation on December 276 due to personal reasons. Meanwhile, Hengrui pharmaceutical announced the appointment of Zhang Xiaojing as deputy general manager and Chief Medical Executive Officer (tumor), and Wang Quanren as deputy general manager. For the appointment of new executives, the deputy general manager of Hengrui pharmaceutical Zhang Lianshan, President of global R & D, said: “we are very glad that Zhang Xiaojing and Wang Quanren have joined the senior management team of Hengrui pharmaceutical, which is also a further embodiment of the specialization of management talents in our R & D field. Their promotion will help Hengrui pharmaceutical further strengthen its internal R & D and innovation capabilities, accelerate the pace of corporate innovation, and bring new momentum to realize the development vision of Hengrui pharmaceutical ‘focusing on innovation and building a Multinational Pharmaceutical Group’.” Over the past year, Hengrui pharmaceutical performed poorly in the capital market and its share price fell all the way. As of the closing on April 12, the share price of Hengrui pharmaceutical was 33.67 yuan / share, and the current total market value is about 215 billion yuan. In January 2021, Hengrui pharmaceutical’s share price reached the highest 116.87 yuan / share. Under the pressure of the share price in the capital market, Hengrui pharmaceutical continued to increase its investment in R & D and innovation. In 2020, the R & D cost of Hengrui medicine was 4.989 billion yuan. In the first three quarters of 2021, the R & D expenses of Hengrui pharmaceutical were 4.142 billion yuan, accounting for 20.51% of the operating revenue, with a year-on-year increase of 23.86%. According to the announcement of Hengrui medicine, Zhang Xiaojing, born in 1977, graduated from Peking Union Medical University and Cancer Hospital of Chinese Academy of Medical Sciences. In 2007, he joined Novartis pharmaceutical and served as the medical director of some products in the field of cancer, responsible for the clinical research and application for listing of some tumor products in China and other Asia Pacific regions. From 2009 to 2019, he worked in Bayer pharmaceutical global R & D Center (China and the United States), and successively served as senior medical expert and global clinical R & D director of some products in the field of cancer. In July 2019, he joined Hengrui pharmaceutical as the deputy general manager of the subsidiary, in charge of the clinical research and development of cancer medicine department, responsible for the clinical development of innovative cancer drugs and the research of unlisted new drugs. Wang Quan, born in 1986, graduated from Shanghai Institute of pharmacy, Chinese Academy of Sciences in 2013 with a doctorate. In 2014, he joined Hengrui pharmaceutical and engaged in the clinical development of new anti-tumor drugs. He has successively served as medical manager, deputy medical director and medical director, during which he presided over the clinical development of multiple class 1 new drugs and combined drugs. From 2021 to now, he has served as the deputy general manager of the subsidiary, in charge of clinical medicine, clinical pharmacology, clinical statistics and other affairs. The relevant person in charge of Hengrui medicine said that Hengrui medicine has long respected the value of talents, took attracting and cultivating talents as an important talent strategy to promote the sustainable development of enterprises, continuously strengthened the talent capacity-building and talent reserve training plan, and comprehensively promoted the layout of innovative and international talents. In recent years, the company’s R & D strength has been continuously strengthened, and the proportion of R & D personnel in the total number of employees has remained stable, providing strong talent support for continuously promoting scientific and technological innovation and international development strategy. It is reported that at present, Hengrui medicine has 10 innovative drugs listed in China, more than 50 innovative drugs are under clinical development, and more than 240 clinical trials have been carried out at home and abroad. Among them, 25 innovative drug projects have been approved to carry out global multi center or regional clinical research, of which 8 are international multi center phase III projects, and a number of studies are in the preparation stage. A total of 86 overseas centers have been launched. Hengrui pharmaceutical has built a number of technical platforms with independent intellectual property rights, covering a wide range of research fields such as kinase inhibitors, antibody drug conjugates (ADC), tumor immunity, hormone receptor regulation, DNA repair and epigenetics, supportive therapy and so on. --- *Originally published on [Debra](https://paragraph.com/@debra/hengrui-pharmaceutical-newly-appoints-two-r-d-executives)*